Rothschild & Co Redburn Begins Coverage on Solventum (NYSE:SOLV)

Rothschild & Co Redburn initiated coverage on shares of Solventum (NYSE:SOLV) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a “sell” rating and a $60.00 price target on the stock. Rothschild & Co Redburn’s price target indicates a potential downside of 7.22% from the stock’s current price.

Several other equities analysts have also weighed in on SOLV. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Stifel Nicolaus boosted their target price on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Piper Sandler restated an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Mizuho set a $100.00 price target on shares of Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Finally, KeyCorp lifted their price objective on shares of Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $90.64.

Solventum Stock Performance

Shares of NYSE SOLV opened at $64.67 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. Solventum has a one year low of $60.70 and a one year high of $88.20. The business’s 50-day moving average price is $73.69 and its two-hundred day moving average price is $75.64. The company has a market capitalization of $11.22 billion, a P/E ratio of 7.29, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Hedge Funds Weigh In On Solventum

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP raised its holdings in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after acquiring an additional 2,456,451 shares during the period. State Street Corp raised its holdings in Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after acquiring an additional 124,490 shares during the period. Davis Selected Advisers lifted its position in Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after acquiring an additional 702,461 shares during the last quarter. Finally, Boston Partners lifted its position in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after acquiring an additional 959,543 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.